Chronic diarrhea caused by primary bile acid diarrhea (PBAD) is a common condition. We have previously shown PBAD is associated with low fasting serum levels of the ileal hormone, fi broblast growth factor 19 (FGF19). FGF19 is a negative regulator of hepatic bile acid synthesis and is stimulated by farnesoid X receptor agonists, which produce symptomatic improvement in PBAD. We aimed to assess possible causes for low serum FGF19 in patients with PBAD.
INTRODUCTION
Bile acid diarrhea (BAD) is a poorly recognized cause of chronic diarrhea and other symptoms such as urgency and fecal incontinence that may otherwise be diagnosed as the irritable bowel syndrome (IBS) (1) (2) (3) (4) . Systematic reviews have suggested that up to 30% of diarrhea-predominant IBS patients, including those meeting Rome III IBS criteria, could have primary BAD (PBAD). Th ese studies used data from abnormal 75 SeHCAT tests, with patients having reduced 7d retention of this labelled bile acid and no obvious cause for bile acid malabsorption ( 2, (5) (6) (7) . SeHCAT values of 10-15% are considered to be mild, 5-10% are moderate, and <5% are severe abnormalities. Other diagnostic tests, including measurement of total fecal bile acids and fasting serum 7α -hydroxy-4-cholesten-3-one (C4), a bile acid precursor, show increased fecal losses and synthesis of bile acids in PBAD ( 3, 4, (8) (9) (10) . Bile acid synthesis is regulated by the ileal hormone fi broblast growth factor 19 (FGF19) in humans, or by its orthologue FGF15 in rodents. FGF15/19 synthesis is stimulated by absorption of bile acids in the ileum, which act through the principal nuclear bile acid receptor, farnesoid X receptor (FXR) to increase transcription by transactivation of specifi c target genes through response elements ( 11, 12 ) . Low FGF15/19 results in increased bile acid synthesis; studies disrupting the FXR-FGF15/19 pathway in animal models have shown increased fecal bile acid loss and chronic diarrhea. Th e evidence for the role of this system has recently been reviewed ( 10 ) . In humans, blood levels of FGF19 and C4 (as a measure of new bile acid synthesis) are inversely correlated and show considerable variation during the day following meals ( 13 ) , in the healthy population overall ( 14 ) , and in patients with IBS ( 3, 15, 16 ) .
Previous studies from our group demonstrated that patients with PBAD have low median fasting serum FGF19 concentrations ( 17 ) . We suggested that this would result in overproduction of bile acids, which could exceed the capacity of the terminal ileum to reabsorb them, and would help explain earlier fi ndings of a larger bile acid pool and no impairment of ileal uptake in PBAD (18) (19) (20) . We have extended this fi nding in a larger prospective series of patients with chronic diarrhea, where PBAD patients have significantly lower, but variable, FGF19 ( 16 ) . Another group has confi rmed low FGF19 in IBS patients with SeHCAT <10% ( 3 ) .
Th e reasons for these varying reductions in FGF19 are currently unclear. Consequently, the aim of these present studies was to determine whether specifi c potential mechanisms could be implicated. We performed a series of diff erent investigations in our defi ned patient population, with bile acid retention defi ned by SeHCAT retention, to identify associated factors that could aff ect FGF19 production and action. First, as variable FGF19 patterns during the day following meals have been identifi ed in preliminary studies in our earlier report, we wished to characterize these more thoroughly and defi ne basal and meal-stimulated responses ( 17 ) . Second, as hypertriglyceridemia has been previously linked to increased bile acid production and absorption, we aimed to determine the extent of this in our PBAD patients ( 14, 21, 22 ) .
We also initiated exploratory studies of certain functional genetic variants, including those which have been identifi ed in the FXR gene ( NR1H4 ) ( 23, 24 ) , which might aff ect FGF19 production. We looked at variants in the FGF19 gene in the 3ʹ-untranslated region that could aff ect transcript stability. Other candidate genes were explored where variation could aff ect intracellular bile acid concentration and FGF19 expression including the ileal bile acid transporters, the apical sodium-dependent bile acid transporter (ASBT, SLC10A2 ) and organic solute transporter-alpha (OSTα, SLC51A ) ( 25 ) . Although they would not be expected to aff ect FGF19 serum levels, variations in the FGF19 receptor, FGFR4 , and its co-receptor, Klotho-β ( KLB ), have been previously been identifi ed in patients with IBS and are related to colonic transit ( 4, 26, 27 ) . Th ese could infl uence the overall responsiveness to FGF19 by aff ecting the specifi c signaling cascade of this hormone. Furthermore, bile acids bind to the cell surface receptor known as TGR5 or GPBAR1 (gene GPBAR1 ), which is expressed on enteric neurons and endocrine cells. TGR5 has been shown to be important for prokinetic actions of bile acids in mice colon, and variants have been associated with human colonic transit, fecal bile acids and IBS-D ( 28 ) . In addition, variants of TNFSF15 have also been associated with IBS-D and could contribute to the disease mechanism ( 29 ) .
Finally, we report separate experiments where we directly determined basal and bile acid-stimulated transcript expression of FGF19 and other key genes in ileal explants obtained from patients with chronic diarrhea with known SeHCAT values. In all these studies, we hypothesized that some of these mechanisms would be abnormal in subgroups of robustly phenotyped patients with PBAD.
METHODS

Patients
Samples from 162 patients with chronic diarrhea were available for study of blood values and genetic variation. 90 of these have been included in a previous report of a prospective series from two sites ( 16 ) . Additional patients were studied for ileal gene expression. Th e composition of patient groups in the diff erent studies is shown in Table 1 .
All patients had a mean stool number of more than three per day, mean stool form on the Bristol stool form scale greater than fi ve, and a duration of more than 3 months. Patients underwent standard testing including blood tests and colonoscopy or fl exible sigmoidoscopy as clinically indicated to exclude other causes of diarrhea such as colorectal neoplasia, celiac or infl ammatory bowel disease. SeHCAT tests were performed as recommended by the manufacturer (GE Healthcare, Amersham, UK). Patients with Se-labelled homocholic acid taurine. a Primary bile acid diarrhea was usually defi ned as SeHCAT <15% 7 day retention. Some studies also analyzed data at 5 and 10% cutoff values. Patients from the previous report ( 16 ) . c Additional patients.
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Ileal FGF19 in Bile Acid Diarrhea 7d SeHCAT retention of <15% were diagnosed as having primary BAD; those with SeHCAT >15% were classed as idiopathic diarrhea controls (ID). Subjects with various secondary causes of BAD, such as Crohn's disease, ileal resection or cholecystectomy, were not included in these studies. Participants gave fully informed consent to be included in research studies as approved by the institutional review board of the Research Ethics Committee of the Hammersmith and Queen Charlottes & Chelsea Hospitals. Fasting blood samples were taken and processed for FGF19, cholesterol and triglycerides and stored for subsequent DNA preparation.
Assays
Serum FGF19 was quantifi ed by a commercially available assay (FGF19 Quantikine ELISA, Cat. No. DF1900; R&D Systems, Minneapolis, MN). Total bile acids were measured by a 3α -hydroxysteroid dehydrogenase assay, and cholesterol and triglycerides were quantifi ed by standard colorimetric techniques in the routine Clinical Chemistry laboratory.
Meal-stimulated FGF19 response
A subgroup of 19 subjects with PBAD was studied to determine post-prandial changes in FGF19 over a 6-h time course. Aft er an overnight fast, blood was sampled every 90 min for 6 h from ~0900 to 1500 hours. Meals were provided aft er the fi rst fasting sample at 0900 (breakfast) and 1200 (lunch) hours. Th e composition of the meals was as follows: breakfast, total weight 395 g, total energy 2,153 KJ, protein: carbohydrate: fat energy ratio 9:71:20%; lunch, total weight 690 g, total energy 2,860 KJ, protein: carbohydrate: fat energy ratio 11: 58: 31%.
Th ree phenotypes of FGF19 response were identifi ed as an arbitrary classifi cation based on our fi ndings: (i) Low-low (L-L), all fi ve serum FGF19 levels <300 pg/ml; (ii) Low-high (L-H), sample 1 <200 pg/ml, sample 4 or 5 >400 pg/ml; (iii) High-high (H-H) samples 1 and 3 or 5 >300 pg/ml. FGF19 area under the curve (AUC) values were calculated.
Genetic polymorphisms
In a separate part of the study, genomic DNA was extracted from 75 subjects by standard techniques with PBAD and 86 ID control subjects. Ten diff erent candidate single-nucleotide polymorphisms were analyzed: two from the gene encoding FGF19 (rs1789170, rs948992), two from FXR (rs61755050, rs56163822), and one each from FGFR4 (rs376618), Klotho-β (rs17618244), ASBT (rs188096), OSTα (rs939885), GPBAR1 (rs11554825) and TNFSF15 (rs7848647). Genotyping of the single-nucleotide polymorphisms was performed using Taqman 5ʹ allelic discrimination assays (Applied Biosystems, Foster City, CA). In exploratory studies we looked at allele frequencies and other genetic models including dominant and recessive genotype diff erences.
Ileal transcript expression
At routine diagnostic ileo-colonoscopy in 31 patients being investigated for unexplained diarrhea, additional biopsies were taken from the ileal mucosa with informed consent. Colonoscopy was performed aft er standard bowel preparation and fasting for at least 6 h. No colonoscopic or histological abnormalities were detected in these patients. All had SeHCAT test results.
In 15 patients, biopsies were immediately stored in RNAlater for subsequent RNA extraction. Th ese provided basal transcript values. In the other 16 patients, bile acid stimulated transcript expression was investigated in explant culture as previously described ( 12 ) . Groups of 2-3 biopsies were incubated separately with either bile acid-free culture media (unstimulated control), or 50 μ mol/l of chenodeoxycholate (CDCA) or glyco-CDCA (GCDCA). Aft er 6 h, biopsies were harvested directly into RNAlater. RNA extraction and complementary DNA synthesis was performed following standard methods. Expression of FGF19 and other transcripts (including ASBT, IBABP, OSTα , OSTβ , SHP, and FXR) were quantifi ed relative to GAPDH by quantitative reverse transcriptase-PCR as previously described ( 12 ) .
Statistics
Data were usually analyzed by non-parametric tests including Mann-Whitney U -test to compare medians and Spearman's Rank correlation ( r s ) to look for associations. Th e parametric Student's t -test was used to compare normally distributed means. In the genetic association studies and other group studies, proportions were compared with Fisher's exact test with two-tailed P values calculated. A P value of <0.05 was considered signifi cant. No corrections in P values were made for multiple comparisons in these relatively small exploratory studies of single-nucleotide polymorphism frequency.
RESULTS
An additional 33 patients with primary BAD (SeHCAT retention<15%) and 39 ID controls (SeHCAT>15%) were recruited and added to those previously reported from our institution ( 16 ) . Th ese had similar clinical fi ndings to those reported before, with median daily stool frequency of 5/d, Bristol stool form types of 6.0-6.5, abdominal pain in 57-63%, bloating in 68-74%, fecal incontinence in 36-39% and presence of symptoms for about 2 years before SeHCAT testing, none of which diff ered significantly between the two groups. Th e median body mass index was higher (27.0 vs. 24.0 kg/m 2 , P =0.009) in the PBAD patients. Biochemical diff erences were again as found previously; in particular the median fasting FGF19 in the overall PBAD group was signifi cantly lower than that in the ID controls (148 vs. 235 pg/ ml, P =0.0005). In the entire group, FGF19 was positively associated with SeHCAT values ( r s =0.33, P =0.0001), with age ( r s =0.23, P =0.002) and with fasting bile acids ( r s =0.32, P <0.0001). FGF19 and body mass index were not signifi cantly related ( r s =−0.11, P =0.09). SeHCAT and body mass index were weakly inversely associated ( r s =−0.19, P =0.01) but SeHCAT and bile acids were not ( r s =−0.03, P =0.71).
Associations of FGF19 with lipids
Th e associations between FGF19 and fasting serum lipids were determined in the patients where these were available.
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Th e strongest associations were found between FGF19 and total cholesterol ( r s =0.33, P =0.009, n =62) and low-density lipoprotein cholesterol ( r s =0.34, P =0.01). Th ere was a non-signifi cant association between FGF19 and high-density lipoprotein cholesterol ( r s =−0.14, P =0.27).
Serum triglycerides fi ndings were notable. Higher FGF19 concentrations were associated with higher serum triglycerides ( r s =0.20, P =0.04). As FGF19 correlates overall with SeHCAT retention, it might have been expected that triglycerides would correlate positively with SeHCAT retention. However, there was a signifi cant negative association between triglycerides and SeHCAT retention ( r s =−0.27, P =0.005, n =106, Figure 1 ). Triglycerides were associated with body mass index ( r s =0.35, P =0.0001), and age ( r s =0.29, P =0.001). Subjects with elevated triglycerides had signifi cantly lower SeHCAT retention (median 8.0 vs. 19.5%, P =0.01). Using cutoff s of triglycerides <2.4 mmol/l and SeHCAT <15% showed a signifi cant segregation ( P =0.017, Fisher's exact test) with most of the subjects with raised triglycerides (13 out of 18) having PBAD with SeHCAT <15%. Furthermore, of the other fi ve subjects with triglycerides ≥2.4 mmol/l, three out of fi ve had SeHCAT retention of under 20%.
In the PBAD group with SeHCAT <15%, those with triglycerides≥2.4 mmol/l had a median FGF19 level, which was significantly higher than that in those with low triglycerides ( Table 2 , P =0.05), and which was similar to the medians found in the ID or healthy control groups. Th ese subjects with elevated triglycerides and low SeHCAT retention may represent a separate subset of about 30% of PBAD with a diff erent underlying etiology.
Meal-stimulated FGF19 responses
We looked at patterns of fasting and meal-stimulated FGF19 to see if we could further defi ne diff erent phenotypes ( Figure 2a-c ) . Based on these patients and previous limited data, we defi ned arbitrary values for low (L) and normal high (H) fasting and mealstimulated values. Although 19 subjects underwent serial FGF19 sampling, two subjects did not match the criteria for the subtypes and are not shown. Of the remaining 17, 8 (47%) were defi ned as having the L-L response, 5 as L-H and 4 as H-H.
Th e eight L-L individuals had signifi cantly lower SeHCAT retention than the L-H group (4.4 vs. 8.1%, P <0.05) and the H-H group (7.4%, P =0.07). In the L-L group, six had SeHCAT retention of 5% or less, with the other two having retention of 6.7% and 11.6%. SeHCAT retention in the fi ve individuals with the L-H pattern was not signifi cantly diff erent to the 4 subjects with the H-H pattern. Th ere were no signifi cant diff erences in clinical and biochemical parameters between these diff erent groups of patients.
Th e FGF19 AUC was lower for those with SeHCAT<5% than those with higher values (median 701 pg/ml·6 h vs. 1,655 pg/ml·6 h, P =0.023). SeHCAT retention correlated with the AUC ( P <0.05, Figure 2d ). AUC tended to be associated with fewer bowel motions in 24 h ( P =0.13). A higher FGF19 taken at the 1500 hours time point was negatively associated with fewer bowel movements per 24 h ( r s =−0.53, P =0.02).
Serum FGF19 and total bile acids at all the time points were related ( r s =0.46, P <0.0001). No signifi cant relationship was found between the percentage change in total bile acids and FGF19 at the same point but they strongly correlated with changes in FGF19 90 min later ( r s =0.51, P <0.001). Th is delay may refl ect the time needed for ileal FGF19 production ( 12 ) and was similar for all three patterns of response.
Th ere were no signifi cant diff erences between the L-L, L-H, or H-H groups in median fasting triglycerides (2.07, 2.65, 0.77 mmol/l) and there was no correlation between fasting triglycerides and FGF19 AUC. Th ere was, however, a strong correlation between fasting triglycerides and the percentage increase in FGF19 aft er breakfast between 0900 and 1030 hours ( r s =0.59, P =0.005). FGF19 rises more with higher fasting triglyceride levels; consistent with the concept that in those subjects with PBAD associated with hypertriglyceridemia, the pathogenesis is not related to a failure of FGF19 production.
Associations with genetic variants
Exploratory studies were performed to look for major diff erences in allelic frequencies of specifi c variants in candidate genes ( Table 3 ). DNA samples from 161 subjects were available but not all genotypes were performed in the entire cohort.
Overall there were no diff erences in allelic frequency that reached signifi cance at the uncorrected P =0.05 level when a SeHCAT cutoff of 15% was used to separate PBAD patients and ID controls. At lower SeHCAT cutoff s, the FGFR4 single-nucleotide 
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Ileal FGF19 in Bile Acid Diarrhea less frequent at SeHCAT values of <10% (uncorrected P =0.01) and <5% ( P =0.05). Overall, TT subjects had a signifi cantly lower SeHCAT to those in the combined CT/CC group (11 vs. 19, P =0.04). However, there was a higher proportion of the C allele in the L-L pheno type compared with the other phenotypes ( P =0.05).
Th e KLB rs17618244 variant had borderline signifi cance, with the minor A allele less frequent in PBAD patients ( P =0.10 to P =0.12 polymorphism rs376618 had borderline signifi cant diff erences, with the minor C allele being less common (see Supplementary Material online for a detailed description).
We also looked at other models for dominant or recessive genotype eff ects. Th e FGFR4 variant rs376618 had borderline signifi cant diff erences in genotype frequency in PBAD compared with ID subjects, with genotypes containing the minor C allele Johnston et al.
depending on SeHCAT cutoff values)
. At the 15% cutoff value, the GG/GA genotypes were more common in the PBAD group ( P =0.07).
Basal levels of transcript expression in ileal biopsies
Expression of FGF19 and other relevant transcripts was studied in ileal biopsies obtained at routine diagnostic colonoscopy from patients with chronic diarrhea who also had SeHCAT tests ( Figure 3 ). Basal expression was studied in 15 patients: 8 had PBAD with SeHCAT values <15% (3 to 13%) and 7 were ID controls (values >15%). Two patients (SeHCAT 5 and 13%) were excluded from further analysis as ASBT, SHP and FGF19 transcript values were below detection limits, suggesting a non-ileal source of these biopsies. SeHCAT values in the 13 patients were signifi cantly associated with FGF19 ( r s =0.59, P =0.03) and with ASBT ( r s =0.49, P =0.04) but not with the other transcripts ( Figure 3a,b ) . Expression of FGF19 and ASBT were strongly correlated ( Figure 3c , r s =0.88, P =0.0002). In addition, IBABP correlated with OSTα ( r s =0.87, P <0.0001) and IBABP with ASBT ( r s =0.63, P =0.01). FXR and SHP expression were associated with several genes in related pathways (FGF19, ASBT, IBABP, OSTα , and each other) but OSTβ did not correlate with any other transcript ( Table 4 ).
All associations were stronger in the ID controls. In the PBAD group, the associations of FGF19 and ASBT with SeHCAT were absent. Although the correlation of FGF19 and ASBT remained strong, those between FXR and OSTα or IBABP were lost.
Stimulation of FGF19 transcript expression in explants
FGF19 expression was studied in 16 patients with diarrhea in ileal explants cultured for 6 h with CDCA, GCDCA, or under control conditions. Both bile acids were used to compare any eff ects that could be related to ASBT uptake of GCDCA compared with more non-specifi c uptake of CDCA. Se-labelled homocholic acid taurine. Spearman's rank correlation coeffi cients ( r s ) and P values are shown for the relationships between expression for all 13 subjects. Signifi cant P values (<0.05) uncorrected for multiple comparisons are shown in bold.
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Ileal FGF19 in Bile Acid Diarrhea with measurements including FGF19, C4, and triglycerides ( 14 ) . Overall they found a negative correlation between FGF19 and corrected C4, and between C4 and triglycerides. In their patients with high C4 above the 95th percentile, 35% had raised triglycerides >2.4 mmol/l. Th is is a similar proportion to that found in our PBAD patients (30%), who would also be expected to have raised C4 ( 30 ) . Patients with familial hypertriglyceridemia have been shown to have an increased rate of bile acid synthesis and abnormal bile acid absorption has been suggested ( 21 ) . Th ese patients have been shown to have reduced expression of ASBT mRNA and protein to about half of control values ( 22 ) , but no putative causative genetic variant that can explain this has been identifi ed ( 31 ) . We have not shown whether these patients with high triglycerides in our cohort with diarrhea have reduced ASBT. It is unclear why they should have essentially normal fasting FGF19 values, but they do appear to constitute a subgroup of about 30% with a markedly altered lipid profi le, meriting further study.
We had found preliminary evidence for diff erent fasting and meal-stimulated FGF19 responses in our initial study of PBAD patients ( 17 ) and now have defi ned these patterns more clearly. Almost half the PBAD patients had the L-L pattern, where fasting and post-prandial samples were all below 200 pg/ml, which differs from the typical meal-stimulated response in healthy subjects shown previously ( 13 ) . Th e lack of signifi cant FGF19 response resembles a normal fasting pattern, but this L-L pattern is also similar to that which we have recently shown in ileal Crohn's disease ( 32 ) . Th ese PBAD patients tend have a more severe phenotype, with a lower SeHCAT, but this pattern can also be found with lesser reductions in SeHCAT. We only studied responses for 6 h and a more prolonged study could yield further patterns. In addition, it is unclear why some patients have the initial high FGF19 of the H-H phenotype; this could be due to prolonged stimulation overnight, lack of fasting or perhaps a stress response related to the demands of the study and venesection.
An impaired hepatic response to FGF19 due to functional genetic variation in components of the receptor pathway (FGFR4, KLB, or further downstream) could also result in excessive bile acid synthesis and high FGF19 levels. Variants in the FGFR4 and KLB genes described by Camilleri and colleagues are particularly interesting in this regard ( 26, 27 ) . Th ey have been shown to be associated with colonic transit and to interact with each other. Furthermore, interactions have previously been demonstrated for KLB variations with GPBAR1 , which codes for the cell-surface bile acid receptor TGR5 and is likely involved with colonic transit ( 28 ) .
We found no overall signifi cant diff erences for any of the gene variants we studied in allele frequency between the PBAD and ID groups, defi ned with a SeHCAT cutoff of 15%. We acknowledge these groups are unpowered and type II errors may have occurred. Th ere were borderline signifi cant diff erences in allelic frequency for FGFR4 at lower SeHCAT cutoff s and in genotype frequencies for the FGFR4 and KLB variants in the small subgroups, and diff erent SeHCAT median values. It must be borne in mind that we have not corrected for multiple comparisons and so the preliminary, exploratory nature of these results must be stressed. Th is study does suggest, however, that these genes represent potential targets FGF19 transcript expression was stimulated in all subjects, with a median of 184-fold induction with CDCA, similar to values found previously in non-diarrheal subjects ( 12 ) . Th e lowest fold changes in FGF19 expression were observed in biopsies from patients with the lowest SeHCAT retention values. Positive correlations were found between SeHCAT retention and the magnitude of the fold change in FGF19 expression stimulated by CDCA ( Figure 3d , r s =0.54, P =0.01, n =16) and by GCDCA ( Figure 3e , r s =0.61, P =0.07, n =7). IBABP, OSTα and SHP transcripts were also signifi cantly stimulated to lesser degrees but ASBT was not aff ected ( Table 5 ) . Apart from FGF19, only the degree of stimulation of IBABP correlated with SeHCAT ( P =0.04).
Th e median stimulation of FGF19 by CDCA was signifi cantly lower in patients with SeHCAT retention <10% ( n =5) compared with those >10% ( n =11) at 16 vs. 182-fold ( P =0.01). Stimulation of IBABP, OSTα , and SHP were not signifi cantly diff erent.
DISCUSSION
In patients with PBAD, defi ned by low SeHCAT retention, we have investigated and shown a variety of mechanisms may be implicated in producing the lower median fasting FGF19 values that we have previously identifi ed. Th ese contributory mechanisms include fasting hypertriglyceridemia and diff erent basal and meal-related responses. We have shown impaired ileal FGF19 transcript expression in the basal state and also impaired bile acid-dependent stimulation. Exploratory studies of possible candidate genetic variation shows only weak associations, which will need confi rmation in larger series, with greater power, but these current fi ndings do indicate there is no large eff ect from any of the particular functional genetic variants we chose to study.
Our studies indicate that diff erent phenotypes can be defi ned in patients with PBAD. Th is may explain the variability we encountered previously in fasting FGF19 serum values, which reduced the predictive value of a single test ( 16 ) . Th e higher FGF19 values found in the patients with fasting hypertriglyceridemia suggest these patients constitute a diff erent subgroup and are in keeping with previous work. Gälman and colleagues studied a large group of over 400 normal subjects without clinical diarrhea, in appropriately powered much larger studies in patients with welldefi ned PBAD. For instance, a study adequately powered (80% at α <0.05) to show the diff erence in proportions we found for the KLB variant would need 500 subjects in each group. However, our fi ndings are a reminder that these patients are predicted to have impaired activity in the bile acid-FXR-FGF19 hormonal pathway but will not have low blood FGF19 levels.
Th e transcript data obtained with ileal biopsies and explant cultures were particularly informative. FGF19 transcripts are significantly lower in basal, unstimulated, fasting samples from patients with lower SeHCAT values. However, ASBT transcripts are also lower; if ASBT protein levels are also reduced, it is likely that this results in reduced bile acid uptake and consequently reduced bile acid/FXR-dependent stimulation of FGF19 transcription. Th is association of ASBT and FGF19 is the strongest of those found in basal levels, which again have not been corrected for multiple comparisons, so the relevance of the weaker associations is less certain. Th is data again will require further confi rmation but this fi nding would be relevant to the reduced fasting FGF19 blood levels we have shown.
Incubation with CDCA also gives FGF19 transcript stimulation that is related to SeHCAT values. Unconjugated CDCA, unlike glycine-conjugated GCDCA, is not dependent on transport by ASBT and will produce FXR-mediated transcription in cells not expressing ASBT ( 33, 34 ) . Conceivably, higher levels of OSTα or IBABP expression would reduce the concentration of intracellular bile acids and the FXR signal, but there is little evidence to support this ( 35 ) . Th e similar relationship of SeHCAT with the stimulation of IBABP, although this is much lower than FGF19 (as also shown before) ( 12 ) , suggests the defect in PBAD extends to at least one other FXR-regulated transcripts. Other reasons for reduced FXR activity and FGF19 induction in the ileum are not clear. Infl ammation in Crohn's ileitis results in lower FGF19 levels ( 32 ) , but the current patients all had normal histological biopsies. Infl ammatory cytokines inhibit FXR and FGF15 in mouse intestine ( 36 ) and could be implicated. FXR activity is aff ected by many other pathways; for instance, intestinal peroxisome proliferatoractivated receptor α -UDP-glucuronosyltransferase signaling has recently been proposed ( 37 ) . Other transcription factors may regulate FGF15/19 transcription. Vitamin D and A responsiveness has been shown in mice ( 38 ) but we found no evidence to support this as being relevant in PBAD patients ( 39 ) . Further possible mechanisms include impaired FXR activity due to SIRT1 downregulation ( 40, 41 ) and the eff ects of the protein Diet1 on FGF19 production ( 42 ) .
Impaired ileal FXR responsiveness is predicted to result in reduced FGF19 production with impaired feedback inhibition of hepatic bile acid synthesis. Th is increased bile acid synthesis leads to excessive fecal bile acid loss (including loss of SeHCAT) and the production of diarrhea. It is of interest to note, however, that patients with PBAD are able to respond to more potent FXR agonists such as obeticholic acid ( 43 ) . In our recent clinical study, 10 PBAD patients who had low median FGF19 but a range of diff erent response patterns all had some increase in FGF19 with treatment. Th is resulted in a median FGF19 that was similar to healthy controls, and gave improvement in clinical fi ndings. It will be instructive to perform further large, placebo-controlled studies where the present fi ndings are taken into account and patients are carefully phenotyped, and genetic variants defi ned, to see if the most responsive patients can be identifi ed.
In conclusion, it appears that several phenotypic patterns of PBAD can be identifi ed (see Figure 4 for a summary of these subgroups). Th ese pathophysiological diff erences can result in diff erent patterns of FGF19, which may not be reduced in some patients with hypertriglyceridemia or possibly with certain receptor genetic variants. Patients with severe PBAD, with SeHCAT retention values <5%, are more likely to have lower meal-related serum FGF19 levels and lower ileal transcript production has been shown. A fuller characterization of these subgroups and their individual pathophysiological causes is needed in larger studies to expand on our exploratory fi ndings, but if confi rmed, an understanding of the diff erent phenotypes of PBAD will help optimize stratifi ed, patient-centered therapy in this understudied condition. 
